Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,359 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04872543RecruitingPhase 2
Study drug for nerve tumor caused by PRC2 loss
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
Basking Ridge, New JerseyAges 16 years+ - NCT04095299RecruitingPhase 3
Standard vs high-dose radiotherapy for rectal cancer
This Phase 3 trial compares standard-dose and higher-dose radiotherapy given along with chemotherapy in people with rectal cancer. The goal is to see whether a higher dose can improve rectal cancer outcomes while keeping the rectum functioning and avoiding too much harm.
AalborgAges 18 years+ - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Chicago, IllinoisAges 6 months–30 years - NCT04794686Recruiting
Study for children with a brain tumor with multilayer rosettes
This registry research program collects information and tumor samples from people with a specific type of brain embryonal tumor (with multilayer rosettes). It may help researchers understand the tumor better and improve future treatments.
Hackensack, New JerseyAges Any age - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04686682RecruitingPhase 1/Phase 2
Study drug for adults with advanced cancers or AML
This early study (Phase 1/2) tests a new medicine (JAB-8263) in adults with advanced solid tumors or recurrent/refractory AML. It aims to find a safe dose and see whether it can shrink tumors or control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04692337Recruiting
Ommaya device for easier testing of brain tumor fluid
This study places a small device in the brain area (called an Ommaya reservoir) so doctors can collect brain fluid to test tumor markers over time. It may help researchers learn more about brain tumors, while also fitting alongside your planned brain surgery at Mayo Clinic.
Rochester, MinnesotaAges 18 years+ - NCT04706910RecruitingPhase 3
PET scan study to optimize imaging in several diseases
This trial improves a special PET scan (a type of brain/body imaging) using 18F-DOPA, to better show how certain conditions behave in the body. If you or your child may have one of the listed conditions, the study may help your doctors get clearer scan results.
Edmonton, AlbertaAges Any age - NCT04690374Recruiting
Registry to Track Health Information in Desmoplastic Tumor
This registry collects health information from people diagnosed with desmoplastic small round cell tumor. Your information helps doctors and researchers better understand the illness over time.
New York, New YorkAges Any age - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT04665206RecruitingPhase 1/Phase 2
Testing VT3989 for certain advanced cancers
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
San Francisco, CaliforniaAges 18 years+ - NCT04621435RecruitingPhase 1
PET imaging test for solid tumors using FAP-2286
This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.
San Francisco, CaliforniaAges 18 years+ - NCT00811148Recruiting
Study for people having brain tumor surgery
This study is for people (children or adults) who are planning brain surgery to remove tumor tissue. It may help researchers learn about care for brain tumors and how outcomes can be improved.
Gainesville, FloridaAges Any age - NCT04570423RecruitingPhase 2
Eflapegrastim safety study for children and teens on chemo
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
Valhalla, New YorkAges 1 month–17 years - NCT04431024Recruiting
Testing imaging and biopsy options for people with BAP1 risk
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
Bethesda, MarylandAges 30–120 - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT04471987RecruitingPhase 1
IL-12 drug for metastatic cancer after checkpoint therapy
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Hamburg, Free and Hanseatic City of HamburgAges 18–80 - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT04339036RecruitingPhase 2
CapTem plus Y-90 for liver-spread neuroendocrine tumors
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
La Jolla, CaliforniaAges 18 years+ - NCT04343365Recruiting
Using tumor evolution to guide treatment choices
This trial uses information from your tumor’s changes over time to help your care team suggest treatment options. It may help people who are unlikely to be cured with standard treatment by testing new, personalized strategy plans.
Tampa, FloridaAges Any age - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Gilbert, ArizonaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,359 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.